| Similar response rates and survival with PARP inhibitors for patients with solid tumors harboring somatic versus Germline BRCA mutations: a Meta-analysis and systematic review GR Mohyuddin, M Aziz, A Britt, L Wade, W Sun, J Baranda, R Al-Rajabi, ... BMC cancer 20, 1-9, 2020 | 60 | 2020 |
| Infection risks in multiple myeloma: a systematic review and meta-analysis of randomized trials from 2015 to 2019 N Balmaceda, M Aziz, VT Chandrasekar, B McClune, S Kambhampati, ... BMC cancer 21, 1-11, 2021 | 30 | 2021 |
| Common Sense Oncology: outcomes that matter CM Booth, M Sengar, A Goodman, B Wilson, A Aggarwal, S Berry, ... The Lancet Oncology 24 (8), 833-835, 2023 | 28 | 2023 |
| Financial toxicity in hematological malignancies: a systematic review E Ouchveridze, R Banerjee, A Desai, M Aziz, W Lee-Smith, H Mian, ... Blood cancer journal 12 (4), 74, 2022 | 23 | 2022 |
| Reporting of postprotocol therapies and attrition in multiple myeloma randomized clinical trials: a systematic review GR Mohyuddin, K Koehn, AO Abdallah, AM Goodman, V Prasad JAMA Network Open 4 (4), e218084-e218084, 2021 | 22 | 2021 |
| Chimeric antigen receptor T-cell therapy in multiple myeloma: A systematic review and meta-analysis of 950 patients GR Mohyuddin, A Rooney, N Balmaceda, M Aziz, DW Sborov, B McClune, ... Blood advances 5 (4), 1097-1101, 2021 | 19 | 2021 |
| Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation A Britt, GR Mohyuddin, B McClune, A Singh, T Lin, S Ganguly, ... Leukemia Research 95, 106402, 2020 | 19 | 2020 |
| Acute generalized exanthematous pustulosis with multiple organ dysfunction syndrome GR Mohyuddin, M Al Asad, L Scratchko, G Khaleeq American Journal of Critical Care 22 (3), 270-273, 2013 | 17 | 2013 |
| Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: a systematic review GR Mohyuddin, K Koehn, AO Abdallah, D W Sborov, SV Rajkumar, ... American journal of hematology 96 (6), 690-697, 2021 | 16 | 2021 |
| Antibiotic prophylaxis for patients with newly diagnosed multiple myeloma: Systematic review and meta‐analysis GR Mohyuddin, M Aziz, B McClune, AO Abdallah, M Qazilbash European journal of haematology 104 (5), 420-426, 2020 | 14 | 2020 |
| Belantamab in combination with dexamethasone in patients with triple-class relapsed/refractory multiple myeloma T Atieh, S Atrash, M Mohan, L Shune, Z Mahmoudjafari, J Quick, J Riffel, ... Blood 138, 1642, 2021 | 13 | 2021 |
| Acknowledging infection risk in bispecific antibody trials in the treatment of multiple myeloma ERS Cliff, G Reynolds, R Popat, BW Teh, AS Kesselheim, GR Mohyuddin Journal of Clinical Oncology 41 (10), 1949-1951, 2023 | 12 | 2023 |
| Quality of control groups in randomised trials of multiple myeloma enrolling in the USA: a systematic review GR Mohyuddin, K Koehn, D Sborov, B McClune, AO Abdallah, ... The Lancet Haematology 8 (4), e299-e304, 2021 | 12 | 2021 |
| A patient with chronic lymphocytic leukemia and acquired angioedema: correlation of clinical and biochemical response to CLL therapy GR Mohyuddin, I Rabinowitz ecancermedicalscience 7, 2013 | 12 | 2013 |
| Hospitalization at the end of life in patients with multiple myeloma S Abbasi, J Roller, AO Abdallah, L Shune, B McClune, D Sborov, ... BMC cancer 21, 1-6, 2021 | 11 | 2021 |
| Outcomes of VD-PACE with immunomodulatory agent as a salvage therapy for relapsed/refractory multiple myeloma AO Abdallah, M Sigle, GR Mohyuddin, E Coggins, C Remker, L Shune, ... Clinical Lymphoma Myeloma and Leukemia 21 (2), e220-e226, 2021 | 11 | 2021 |
| Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis G Reynolds, ERS Cliff, GR Mohyuddin, R Popat, S Midha, MN Liet Hing, ... Blood Advances 7 (19), 5898-5903, 2023 | 10 | 2023 |
| Synthetic control arms in studies of multiple myeloma and diffuse large B‐cell lymphoma R Banerjee, S Midha, AH Kelkar, A Goodman, V Prasad, GR Mohyuddin British Journal of Haematology 196 (5), 1274-1277, 2022 | 10 | 2022 |
| Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple‐class relapsed/refractory multiple myeloma (RRMM) D Pennipede, GR Mohyuddin, R Hawkins, S Ganguly, L Shune, N Ahmed, ... European Journal of Haematology 107 (6), 602-608, 2021 | 10 | 2021 |
| Intention to treat versus modified intention-to-treat analysis in B-cell maturation antigen and CD19 chimeric antigen receptor trials: a systematic review and meta-analysis GR Mohyuddin, T Atieh, N Ahmed, D Sborov, B McClune, AO Abdallah, ... European Journal of Cancer 156, 164-174, 2021 | 9 | 2021 |
